.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,528,104

« Back to Dashboard
Patent 7,528,104 protects OMONTYS and OMONTYS PRESERVATIVE FREE and is included in one NDA.

This patent has twenty-two patent family members in twenty-one countries.

Summary for Patent: 7,528,104

Title:Peptides that bind to the erythropoietin receptor
Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
Inventor(s): Holmes; Christopher P. (Saratoga, CA), Yin; Qun (Palo Alto, CA), Lalonde; Guy (Woodside, CA), Schatz; Peter J. (Cupertino, CA), Tumelty; David (Sunnyvale, CA), Palani; Balu (Cupertino, CA), Zemede; Genet (Santa Clara, CA)
Assignee: Affymax, Inc. (Palo Alto, CA)
Application Number:10/555,868
Patent Claim Types:
see list of patent claims
Compound; Composition;
Patent Metrics:
Source: PatentQuant.com
Field: Basic materials chemistry
Back Citations: 87th percentile
Forward Citations: 7th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Takeda Pharms Usa
OMONTYS
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-007Mar 27, 2012DISCNNo7,528,104► subscribeYY
Takeda Pharms Usa
OMONTYS
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-008Mar 27, 2012DISCNNo7,528,104► subscribeYY
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-001Mar 27, 2012DISCNNo7,528,104► subscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,528,104

PCT Information
PCT FiledMay 12, 2004PCT Application Number:PCT/US2004/014886
PCT Publication Date:November 25, 2004PCT Publication Number: WO2004/101611

Non-Orange Book Patents for Patent: 7,528,104

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,304,391Peptides that bind to the erythropoietin receptor► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,528,104

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia1625156► subscribe
Portugal1625156► subscribe
New Zealand543935► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc